1. Inicio
  2. Proyectos y Estudios
  3. A NON-INTERVENTIONAL, MULTI-NATIONAL, MULTI-CENTER POST-AUTHORIZATION SAFETY STUDY (PASS) TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF ODOMZO® (SONIDEGIB) ADMINISTERED IN PATIENTS WITH LOCALLY ADVANCED BASAL CELL CARCINOMA (LABCC): NISSO.

A NON-INTERVENTIONAL, MULTI-NATIONAL, MULTI-CENTER POST-AUTHORIZATION SAFETY STUDY (PASS) TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF ODOMZO® (SONIDEGIB) ADMINISTERED IN PATIENTS WITH LOCALLY ADVANCED BASAL CELL CARCINOMA (LABCC): NISSO.

Datos básicos

ESTUDIO OBSERVACIONAL SPI-SON-2020-01 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2021 Año de finalización: 2025

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

SUN PHARMACEUTICAL INDUSTRIES EUROPE B.V.

Cita

Compartir